Delivery Order SPE2DB22D9112-SPE2DB24FE6SV
Award Date 4/1/24
Potential Completion Date 4/22/24
Potential Value $4.6K
Federal Agency
Ultimate Awardee
Not listed PSC Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Park Ridge, IL 60068, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- The U.S. Defense Logistics Agency (DLA) awarded a Firm Fixed Price Delivery Order contract to DMS Pharmaceutical Group Inc., a woman-owned small business, to supply 4,561,964,058 units of Xolair 150 mg/ml syringe for $15,474.00. This order is part of DMS Pharmaceutical Group's larger Indefinite Delivery Contract (IDC) with the DLA, valued at up to $499,999,999, to provide a wide range of pharmaceutical products and medical supplies to support the recurring medical needs of military health...
- The U.S. Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order contract to DMS Pharmaceutical Group Inc., a woman-owned small business. The contract, valued at $3,094.80, is to provide the DLA with 4564570218 - XOLAIR 150 MG/ML SYRINGEML. This order is part of a larger indefinite delivery contract (IDC) with DMS Pharmaceutical Group that has a ceiling value of up to $499,999,999. The IDC, awarded under the DLA's SPE2DB program, allows the agency to issue delivery orders for...
- The Defense Logistics Agency (DLA) awarded a firm fixed price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business, to provide Xolair 150 mg/ml syringes. The total potential value of the order is $18,568.80, with a completion date of February 8, 2024. This delivery order is part of a larger indefinite delivery contract held by DMS Pharmaceutical Group Inc. to supply a variety of pharmaceutical and medical products, including items such as flumazenil injection, prednisone...
- The U.S. Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order contract to DMS Pharmaceutical Group Inc., a woman-owned small business, for the supply of Xolair 150 mg/mL syringes. The contract, valued at $9,284.40, has an ultimate completion date of April 23, 2024. This delivery order falls under DMS Pharmaceutical Group's existing indefinite delivery contract, SPE2DB22D9362, with the DLA worth up to $4,999,999 through the end of 2025. This larger contract enables the DLA...
- The Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order valued at $7,737.00 to DMS Pharmaceutical Group Inc., a woman-owned small business, for the supply of Xolair 75 mg/0.5 ml syringes. This delivery order is part of a larger indefinite delivery vehicle (IDV) contract, contract 4600082013 under the SPE2DB program, valued up to $4,999,999 through 2025 that enables DLA to place orders for a broad range of pharmaceutical items to support the recurring medical supply needs...
- The U.S. Defense Logistics Agency (DLA) awarded a $6,189.60 firm-fixed-price delivery order contract to DMS Pharmaceutical Group Inc., a woman-owned small business, for the provision of Xolair 150 mg/ml syringes. This delivery order was issued under the DLA's Medical Supply Chain SPE2DB Indefinite Delivery Contract, a $499,999,999 single-award vehicle that enables the DLA to procure a comprehensive range of pharmaceutical products to support the recurring medical supply needs of military...
- The U.S. Defense Logistics Agency (DLA) awarded a Firm Fixed Price delivery order contract worth $3,094.80 to DMS Pharmaceutical Group Inc., a woman-owned small business. The contract is for the delivery of XOLAIR 150 MG/ML syringes and has a performance period through May 2, 2024. This award is placed against DMS Pharmaceutical Group's existing indefinite delivery contract SPE2DB with DLA, valued at up to $4,999,999 through 2025. Under this broader contract vehicle, DMS Pharmaceutical Group...
- The U.S. Defense Logistics Agency (DLA) awarded a Firm Fixed Price Delivery Order contract worth $6,189.60 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler, for the delivery of 4565190539 ! XOLAIR 150 MG/ML SYRINGEML. This order is part of a larger Indefinite Delivery Contract (IDC) valued up to $499,999,999 that DMS Pharmaceutical Group holds with DLA to provide a comprehensive range of pharmaceutical products to support the medical supply needs of...
- The U.S. Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler, for the supply of XOLAIR 150 MG/ML syringes. The total ceiling value of the order is $77,370.00, with an ultimate completion date of September 23, 2024. This delivery order is part of a larger $499,999,999 indefinite delivery contract (IDC) between DMS Pharmaceutical Group and the DLA under the SPE2DB program, which covers a...
- The Defense Logistics Agency (DLA) awarded a $22,606.44 firm fixed-price delivery order contract to DMS Pharmaceutical Group Inc., a woman-owned small business, for the provision of 4,566,263 units of the pharmaceutical product Xolair 300 mg/2 ml syringe. This delivery order is part of a larger Indefinite Delivery Contract (IDC) valued at $499,999,999 that DMS Pharmaceutical Group holds with the DLA under the SPE2DB program. The contract covers a comprehensive range of pharmaceutical products,...